New Imported Drug Approvals by the NMPA - September 2024 | China Medical News

October: New Imported Drug Approvals by the NMPA - September 2024

□　Osilodrostat Phosphate Tablets (Brand; Shi Rui Sa) – marketed by Recordati Rare Diseases
□　Pembrolizumab Injection (Brand; Keytruda) – new indication for 1L in unresectable or metastatic melanoma - marketed by Merck Sharp & Dohme LLC
□　Ponatinib Tablets (Brand; ICLUSIsG) – marketed by Otsuka Pharmaceutical Co., Ltd.
□　Tofersen Injection (Brand; Qalsody) – marketed by Biogen MA Inc.
□　Turoctocog alfa pegol for injection (Brand; Esperoct) – new indication not yet disclosed - marketed by Novo Nordisk A/S

(Source: BaiPharm)